Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Wake Forest University Health Sciences
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT03475186
This study is to determine if an oral drug called Ramipril can lower the chance of memory
loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during
chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using
several neurocognitive tests throughout the duration of the study.
Glioblastoma, Radiotherapy; Complications, Cognitive Decline, Chemoradiation
Michael D Chan, MD, Daniel H. Barnett, Aaron G. Mammoser, Anand Mahadevan, Volker W. Stieber, Pamala A. Pawloski, Timothy D. Moore, Bryan A. Faller, Collin D. Driscoll, Richard M. Green, Robert J. Behrens, Preston D. Steen, Bret E. Friday, Scott M. Lindhorst, Benjamin E. Lawler, Vinay K. Gudena, Kathleen J. Yost, Gena H. Volas-Redd, Richard L. Deming, Benny J. Liem, Howard A. Zaren, Glenn J. Lesser, Robert J. Isaak, Jay W. Carlson, James E. Radford, Alison K Conlin, Richard L Deming, Jay W Carlson, Daniel H Barnetter, Timothy D Moore, Gregory A Masters, Samir Narayan, Stuart Y Tsuji, Daniel H Barnett, Bryan A Faller, Thomas E Lad, Joshua Lukenbill, Seth J Page, Gary V Burton, Kathleen J Yost, Bret EB Friday, Preston D Steen, Pamala A Pawloski, Pamela A Pawloski, Vinay K Gudena, Glenn J Lesser, Volker W Stieber, Benny J Liem, Ki Y Chung, Howard A Zaren, Harish G Ahuja, Asadullah Khan, Katherine A Conlin

See list of participating sites